Study protocol of European Fans in Training (EuroFIT) : a four-country randomised controlled trial of a lifestyle program for men delivered in elite football clubs

Funding The EuroFIT study is funded by the European Union’s Seventh Framework Program for research technological development and demonstration under Grant Agreement no: 602170. The Health Services Research Unit, University of Aberdeen, is core funded by the Chief Scientist Office of the Scottish Government Health Directorates.

Size and variability of crop productivity both impacted by CO2 enrichment and warming-A case study of 4 year field experiment in a Chinese paddy

Acknowledgement Construction and maintenance of the experiment system was funded by the state Special Fund for Agro-scientific Research in the Public Interest “Climate Change Impacts on Crop Production and Mitigation” under a grant number 200903003. This work was financially supported by Ministry of Science and Technology of China under a grant number 2012BAC19B01 and Department of Science and Technology of Jiangsu province under a grant number BK20150684. The international cooperation was funded by “111 project” (B12009) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). The contribution of Pete Smith was funded by the Chinese Ministry of Agriculture and the United Kingdom Department for Environment, Food and Rural Affairs (DEFRA) under UK-China Sustainable Agriculture Innovation Network (SAIN). The contribution of Timothy Filley was also funded by the state foreign expert agency under a project of Foreign High-end expert program. The authors thank Jiangsu Tianniang Agro-Technology Company Ltd. for the assistance in maintaining the experiment system.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Acknowledgments The VIVIANE study was funded and coordinated by GlaxoSmithKline Biologicals SA, which also covered all costs associated with development and publication of this report. We thank all study participants and their families. We gratefully acknowledge the work of the central and local study coordinators, and staff members of the sites who participated in this study. Writing support services were provided by Mary Greenacre (An Sgriobhadair, Isle of Barra, UK), on behalf of GSK Vaccines; editing and publication coordination services were provided by Jérôme Leemans (Keyrus Biopharma, Lasne, Belgium), Stéphanie Delval (XPE Pharma and Science, Wavre, Belgium), and Matthieu Depuydt (Business Decision Life Sciences, Brussels, Belgium), on behalf of GSK Vaccines